Vivian Bykerk, MD: Treating RA Early
Vivian Bykerk, MD, associate attending rheumatologist at the Hospital for Special Surgery, associate professor of medicine at Weill Cornell Medical College, explains why treating rheumatoid arthritis (RA) early is crucial.
Transcript:
Why is it important for patients with RA to get treatment early in the course of their disease?
You can imagine, if you allow each joint to be infiltrated with a large number of immune cells that are creating messengers, we call them cytokines, and other messengers that seek to destroy, basically cause damage, that you don’t ever want those joints to get to that stage.
In other words, we want to meet people when they’re first developing achiness and maybe the first swollen joint, so that we can literally control that and limit—modify the disease, in essence—the development of proliferative synovial tissue in the joint that causes damage.
Once that horse is out of the barn, it’s really hard to manage it. It’s possible, but it usually requires a whole level up, in terms of therapy.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
